IMCR vs. BPMC, SRPT, TLX, AXSM, KRYS, NUVL, GRFS, ELAN, VRNA, and ADMA
Should you be buying Immunocore stock or one of its competitors? The main competitors of Immunocore include Blueprint Medicines (BPMC), Sarepta Therapeutics (SRPT), Telix Pharmaceuticals Limited American Depositary Shares (TLX), Axsome Therapeutics (AXSM), Krystal Biotech (KRYS), Nuvalent (NUVL), Grifols (GRFS), Elanco Animal Health (ELAN), Verona Pharma (VRNA), and ADMA Biologics (ADMA). These companies are all part of the "pharmaceutical products" industry.
Immunocore vs.
Blueprint Medicines (NASDAQ:BPMC) and Immunocore (NASDAQ:IMCR) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their community ranking, analyst recommendations, media sentiment, earnings, institutional ownership, valuation, profitability, risk and dividends.
Blueprint Medicines currently has a consensus price target of $124.95, suggesting a potential upside of 50.96%. Immunocore has a consensus price target of $63.73, suggesting a potential upside of 136.90%. Given Immunocore's higher possible upside, analysts clearly believe Immunocore is more favorable than Blueprint Medicines.
Blueprint Medicines has a beta of 0.75, meaning that its stock price is 25% less volatile than the S&P 500. Comparatively, Immunocore has a beta of 0.75, meaning that its stock price is 25% less volatile than the S&P 500.
84.5% of Immunocore shares are held by institutional investors. 4.2% of Blueprint Medicines shares are held by insiders. Comparatively, 9.1% of Immunocore shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Blueprint Medicines has a net margin of -13.19% compared to Immunocore's net margin of -15.87%. Immunocore's return on equity of -12.84% beat Blueprint Medicines' return on equity.
In the previous week, Blueprint Medicines and Blueprint Medicines both had 10 articles in the media. Blueprint Medicines' average media sentiment score of 0.93 beat Immunocore's score of 0.07 indicating that Blueprint Medicines is being referred to more favorably in the media.
Immunocore has lower revenue, but higher earnings than Blueprint Medicines. Blueprint Medicines is trading at a lower price-to-earnings ratio than Immunocore, indicating that it is currently the more affordable of the two stocks.
Blueprint Medicines received 478 more outperform votes than Immunocore when rated by MarketBeat users. However, 73.47% of users gave Immunocore an outperform vote while only 68.15% of users gave Blueprint Medicines an outperform vote.
Summary
Immunocore beats Blueprint Medicines on 9 of the 17 factors compared between the two stocks.
Get Immunocore News Delivered to You Automatically
Sign up to receive the latest news and ratings for IMCR and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Immunocore Competitors List
Related Companies and Tools
This page (NASDAQ:IMCR) was last updated on 4/15/2025 by MarketBeat.com Staff
Buy IMCR Stock Free IMCR Stock Alerts